Type of immunotherapy Passive or active Example Advantages Disadvantage References Adaptive cellular therapy TIL Passive N/A Limited TILs for in vitro expansion A personalized approach and costly N/A CAR-T Passive Mesothelin…
© Springer Science+Business Media Singapore 2017Hiroki Yamaue (ed.)Innovation of Diagnosis and Treatment for Pancreatic Cancerhttps://doi.org/10.1007/978-981-10-2486-3_12 12. Distal Pancreatectomy for Pancreatic Carcinoma Masayuki Sho1 and Shoichi Kinoshita1 (1) Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara Nara,…
Fig. 5.1 Liquid biopsy in pancreatic cancer. Tumor-specific alterations can be detected in circulating tumor DNA (ctDNA) in blood. Detecting ctDNA in plasma or serum serves as a “liquid biopsy,”…
Sex cord-stromal tumors Pure stromal tumors Fibroma Cellular fibroma Thecoma Luteinized thecoma associated with sclerosing peritonitis Fibrosarcoma Sclerosing stromal tumor Signet-ring stromal tumor Microcystic stromal tumor Leydig cell tumor Steroid…
Fig. 5.1 Serous tubal intraepithelial carcinoma. Proliferation of epithelial cells with high-grade atypia replaces the surface of tubal fimbrial epithelium. (a) low power, (b) high power Fig. 5.2 p53 signature….
Type <20 years 20–50 years >50 years Coelomic epithelium 29% 71% 81% Germ cell 59% 14% 6% Specialized gonadal stroma 8% 5% 4% Non-specific mesenchyme 4% 10% 9% Some patients with ovarian cancer…
SEER (NCI) 15–29-year-old Adolescent and young Adult Oncology Progress Review Group 15–39-year-old NCCN 15–39-year-old 15.3 Cancer in AYAs Worldwide Including Ovarian Cancer In the United States, 70,000 AYAs are diagnosed…
Fig. 9.1 Serous borderline tumor, micropapillary pattern. Non-hierarchial pattern is shown with micropapillary projection five times longer than width at least 5 mm in dimension with fibrous stalks The prognosis…
Specificity activation Non-specific (activate systemic immunity, relatively old) Specific (target cancer cells or cancer-specific antigens, relatively old) Active immunization (to elicit immunity in vivo) Biological response modifier Cancer vaccine Dendritic…
Fig. 17.1 (a) Institutions where end-of-life care was provided [33]. (b) Waiting periods for transfer to a palliative care unit [33] Fig. 17.2 (a) Treatment modalities for managing ascites (multiple…
